192 related articles for article (PubMed ID: 33094705)
1. Caffeine and caffeine-containing pharmaceuticals as promising inhibitors for 3-chymotrypsin-like protease of SARS-CoV-2.
Elzupir AO
J Biomol Struct Dyn; 2022 Mar; 40(5):2113-2120. PubMed ID: 33094705
[TBL] [Abstract][Full Text] [Related]
2. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.
Elzupir AO
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540
[TBL] [Abstract][Full Text] [Related]
3. Identification of potential bioactive natural compounds from Indonesian medicinal plants against 3-chymotrypsin-like protease (3CL
Prasetyo WE; Purnomo H; Sadrini M; Wibowo FR; Firdaus M; Kusumaningsih T
J Biomol Struct Dyn; 2023 Jul; 41(10):4467-4484. PubMed ID: 35470785
[TBL] [Abstract][Full Text] [Related]
4. Binding and inhibitory effect of ravidasvir on 3CL
Bera K
J Biomol Struct Dyn; 2022 Oct; 40(16):7303-7310. PubMed ID: 33682639
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 M
Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
[TBL] [Abstract][Full Text] [Related]
6. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
[TBL] [Abstract][Full Text] [Related]
7. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.
Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM
Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SARS-CoV-2 main protease 3CL
Elzupir AO
J Mol Struct; 2020 Dec; 1222():128878. PubMed ID: 32834113
[TBL] [Abstract][Full Text] [Related]
9. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
[TBL] [Abstract][Full Text] [Related]
10. Elucidation of the inhibitory activity of plant-derived SARS-CoV inhibitors and their potential as SARS-CoV-2 inhibitors.
Bello M; Hasan MK
J Biomol Struct Dyn; 2022; 40(20):9992-10004. PubMed ID: 34121618
[TBL] [Abstract][Full Text] [Related]
11. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.
Wang Y; Gao Q; Yao P; Yao Q; Zhang J
J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210
[TBL] [Abstract][Full Text] [Related]
12. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
13. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
[TBL] [Abstract][Full Text] [Related]
14.
Iype E; Pillai U J; Kumar I; Gaastra-Nedea SV; Subramanian R; Saha RN; Dutta M
J Biomol Struct Dyn; 2022; 40(23):12800-12811. PubMed ID: 34550861
[TBL] [Abstract][Full Text] [Related]
15. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
[TBL] [Abstract][Full Text] [Related]
16.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
17. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening of approved clinic drugs with main protease (3CL
Wang Q; Zhao Y; Chen X; Hong A
J Biomol Struct Dyn; 2022 Feb; 40(2):685-695. PubMed ID: 32909528
[TBL] [Abstract][Full Text] [Related]
19. Fourteen immunomodulatory alkaloids and two prenylated phenylpropanoids with dual therapeutic approach for COVID-19: molecular docking and dynamics studies.
Omar R; Abd El-Salam M; Elsbaey M; Hassan M
J Biomol Struct Dyn; 2024 Mar; 42(5):2298-2315. PubMed ID: 37116054
[TBL] [Abstract][Full Text] [Related]
20. In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.
Gul S; Ozcan O; Asar S; Okyar A; Barıs I; Kavakli IH
J Biomol Struct Dyn; 2021 Oct; 39(17):6772-6791. PubMed ID: 32752938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]